Functional and surgical outcomes of Aquablation in elderly men.


Journal

World journal of urology
ISSN: 1433-8726
Titre abrégé: World J Urol
Pays: Germany
ID NLM: 8307716

Informations de publication

Date de publication:
Oct 2022
Historique:
received: 23 05 2022
accepted: 11 08 2022
pubmed: 31 8 2022
medline: 28 9 2022
entrez: 30 8 2022
Statut: ppublish

Résumé

As benign prostatic hyperplasia (BPH) is an age-related process, growing interest in surgical management for elderly men has emerged. Recently, Aquablation was approved for treatment of BPH associated lower urinary tract symptoms (LUTS) and utilizes robotic ultrasound guided surgeon-controlled waterjet ablation. We assessed the differences in functional and surgical outcomes between elderly and young men undergoing Aquablation for BPH/LUTS. We retrospectively assessed prospectively collected data from the WATER I (NCT02505919) and WATER II (NCT03123250) clinical trials reporting safety and efficacy of Aquablation in the treatment of LUTS/BPH in men 45-80 years with a prostate between 30 and 80 cc, and 80 cc and 150 cc, respectively. Men ≥ 65 years were defined as elderly and men < 65 years as young. Of 217 patients included, 83 (38.2%) were young and 134 (61.8%) were elderly. Mean age (SD) was 59.3 (± 3.4) years and 71.2 (± 4.2) years for young and elderly men, respectively. At 3 years of follow-up compared to baseline, elderly men showed similar reductions in total IPSS (7.68 points vs 7.12 points, p > 0.05) and similar increases in Qmax (20.6 mL/s vs 19.3 mL/s, p > 0.05) compared to young men. The ejaculatory dysfunction rate was similar for both cohorts (12.0% vs 9.7%, p > 0.05). Elderly men experienced similar annual retreatment rates compared to young men (1.5% vs 0.8% p > 0.05). Elderly men undergoing Aquablation have similar functional and surgical outcomes as young men. Elderly patient BPH surgical counseling should, therefore, consider Aquablation as a treatment option for LUTS/BPH.

Identifiants

pubmed: 36040501
doi: 10.1007/s00345-022-04137-6
pii: 10.1007/s00345-022-04137-6
doi:

Substances chimiques

Water 059QF0KO0R

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2515-2520

Commentaires et corrections

Type : CommentIn

Informations de copyright

© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Références

Bushman W (2009) Etiology, epidemiology, and natural history of benign prostatic hyperplasia. Urol Clin North Am 36(4):403–415
doi: 10.1016/j.ucl.2009.07.003
Bortnick E, Brown C, Simma-Chiang V, Kaplan SA (2020) Modern best practice in the management of benign prostatic hyperplasia in the elderly. Ther Adv Urol 12:1756287220929486
doi: 10.1177/1756287220929486
Piao S, Choo MS, Kim M, Jeon HJ, Oh SJ (2016) Holmium laser enucleation of the prostate is safe for patients above 80 years: a prospective study. Int Neurourol J 20(2):143–150
doi: 10.5213/inj.1630478.239
Elshal AM, Elmansy HM, Elhilali MM (2013) Transurethral laser surgery for benign prostate hyperplasia in octogenarians: safety and outcomes. Urology 81(3):634–639
doi: 10.1016/j.urology.2012.11.042
Holman CD, Wisniewski ZS, Semmens JB, Rouse IL, Bass AJ (1999) Mortality and prostate cancer risk in 19,598 men after surgery for benign prostatic hyperplasia. BJU Int 84(1):37–42
doi: 10.1046/j.1464-410x.1999.00123.x
Gilling P, Reuther R, Kahokehr A, Fraundorfer M (2016) Aquablation–image-guided robot-assisted waterjet ablation of the prostate: initial clinical experience. BJU Int 117(6):923–929
doi: 10.1111/bju.13358
Sadri I, Arezki A, Couture F, Nguyen DD, Schwartz R, Zakaria AS et al (2021) Reasons to overthrow TURP: bring on Aquablation. World J Urol 39(7):2291–2299
doi: 10.1007/s00345-020-03390-x
Bach PDMT, Barber N, Elterman D et al (2022) Aquablation outcomes in men with LUTS due to BPH following single versus multi-pass treatments. Urology S0090–4295(22):00599–00604. https://doi.org/10.1016/j.urology.2022.07.007
doi: 10.1016/j.urology.2022.07.007
Elmansy H, Baazeem A, Kotb A, Badawy H, Riad E, Emran A et al (2012) Holmium laser enucleation versus photoselective vaporization for prostatic adenoma greater than 60 ml: preliminary results of a prospective, randomized clinical trial. J Urol 188(1):216–221. https://doi.org/10.1016/j.juro.2012.02.2576
doi: 10.1016/j.juro.2012.02.2576 pubmed: 22591968
Gao B, Lu S, Bhojani N, Zorn KC, Chughtai B, Elterman D (2021) Office-Based procedures for BPH. Curr Urol Rep 22(12):63. https://doi.org/10.1007/s11934-021-01081-7
doi: 10.1007/s11934-021-01081-7 pubmed: 34913101
Chughtai B, Thomas D (2018) Pooled Aquablation results for American men with lower urinary tract symptoms due to benign prostatic hyperplasia in large prostates (60–150 cc). Adv Ther 35(6):832–838
doi: 10.1007/s12325-018-0722-0
Kim JK, Cho MC, Son H, Ku JH, Oh SJ, Paick JS (2017) Patient perception of ejaculatory volume reduction after Holmium Laser Enucleation of the Prostate (HoLEP). Urology 99:142–147
doi: 10.1016/j.urology.2016.09.037
Ghobrial FK, Shoma A, Elshal AM, Laymon M, El-Tabey N, Nabeeh A et al (2020) A randomized trial comparing bipolar transurethral vaporization of the prostate with GreenLight laser (xps-180watt) photoselective vaporization of the prostate for treatment of small to moderate benign prostatic obstruction: outcomes after 2 years. BJU Int 125(1):144–152
doi: 10.1111/bju.14926
Gilling P, Barber N, Bidair M, Anderson P, Sutton M, Aho T et al (2020) Three-year outcomes after Aquablation therapy compared to TURP: results from a blinded randomized trial. Can J Urol 27(1):10072–10079
pubmed: 32065861
Nguyen DD, Misraï V, Bach T, Bhojani N, Lingeman JE, Elterman DS et al (2020) Operative time comparison of Aquablation, greenlight PVP, ThuLEP, GreenLEP, and HoLEP. World J Urol 38(12):3227–3233
doi: 10.1007/s00345-020-03137-8
Bozzini G, Berti L, Aydoğan TB, Maltagliati M, Roche JB, Bove P et al (2021) A prospective multicenter randomized comparison between Holmium Laser Enucleation of the Prostate (HoLEP) and Thulium Laser Enucleation of the Prostate (ThuLEP). World J Urol 39(7):2375–2382
doi: 10.1007/s00345-020-03468-6
Garden EB, Ravivarapu KT, Levy M, Chin CP, Omidele O, Tomer N et al (2022) The utilization and safety of same-day discharge after transurethral benign prostatic hyperplasia surgery: a case-control, matched analysis of a national cohort. Urology S0090–4295(22):00095–00104
Mmeje CO, Nunez-Nateras R, Warner JN, Humphreys MR (2013) Age-stratified outcomes of holmium laser enucleation of the prostate. BJU Int 112(7):982–989. https://doi.org/10.1111/bju.12063
doi: 10.1111/bju.12063 pubmed: 23510326
Gu X, Strom K, Spaliviero M, Wong C (2012) Does age affect the efficacy and safety of GreenLight HPS
doi: 10.3109/13685538.2011.632452 pubmed: 22129103
Stout TE, Fazio A, Walczak EG, Ordonez M (2021) Evaluating the perceived importance of male ejaculatory function. Urology 147:162–166
doi: 10.1016/j.urology.2020.09.020
Bouhadana D, Nguyen DD, Zorn KC, Elterman DS, Bhojani N (2020) Patient perspectives on benign prostatic hyperplasia surgery: a focus on sexual health. J Sex Med 17(10):2108–2112
doi: 10.1016/j.jsxm.2020.07.006

Auteurs

Brendan L Raizenne (BL)

Division of Urology, Centre Hospitalier de l'Université de Montréal, 900 St. Denis, Montréal, QC, H2X 0A9, Canada. brendanraizenne@gmail.com.

David Bouhadana (D)

Faculty of Medicine, Mcgill University, Montréal, QC, Canada.

Kevin C Zorn (KC)

Division of Urology, Centre Hospitalier de l'Université de Montréal, 900 St. Denis, Montréal, QC, H2X 0A9, Canada.

Neil Barber (N)

Department of Urology, Frimley Park Hospital, Frimley, UK.

Peter Gilling (P)

Department of Urology, Bay of Plenty District Health Board Clinical School, Tauranga, New Zealand.

Steven Kaplan (S)

Department of Urology, Mount Sinai Hospital, New York, NY, USA.

Gopal Badlani (G)

Department of Urology, Wake Forest School of Medicine, Winston-Salem, NC, USA.

Bilal Chughtai (B)

Department of Urology, Weill Cornell Medical College/New York Presbyterian, New York, NY, USA.

Dean Elterman (D)

Division of Urology, University Health Network, University of Toronto, Toronto, ON, Canada.

Naeem Bhojani (N)

Division of Urology, Centre Hospitalier de l'Université de Montréal, 900 St. Denis, Montréal, QC, H2X 0A9, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH